Modulation of diabetes and dyslipidemia in diabetic insulin-resistant rats by mangiferin: Role of adiponectin and TNF-α
Open accessAbstract
Mangiferin, present in Mangifera indica bark, was reported to produce hypoglycemic and antidiabetic activity in an animal model of genetic type 2 diabetes and in streptozotocin diabetic rats. Its effect on diabetic insulin-resistant animals has not been investigated. The current work aimed to explore the effect of mangiferin on diabetic insulin-resistant rat model. Diabetes was induced by high-fat/high fructose diet for eight weeks followed by a subdiabetogenic dose of streptozotocin (HFD-Fr-STZ). Rats were treated with mangiferin (20 mg/kg i.p.) for 28 days starting one week after STZ and its effects were compared to the standard insulin sensitizer, rosiglitazone. HFD-Fr-STZ, induced obesity, hyperglycemia and insulin resistance accompanied by depletion in liver glycogen and dyslipidemia. Moreover, there was an elevation in serum TNF-α and a reduction in adiponectin. Mangiferin ameliorated the consequences of HFD-Fr-STZ and its actions were comparable to the effects of the standard insulin sensitizer, rosiglitazone. The results obtained in this study provide evidence that mangiferin is a possible beneficial natural compound for type 2 diabetes and metabolic disorders associated with the metabolic syndrome. This effect is mediated through improving insulin sensitivity, modulating lipid profile and reverting adipokine levels to normal.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a high-fat high fructose diet and STZ-induced diabetic insulin-resistant rat model, mangiferin alleviated insulin resistance, improved beta-cell function, reduced serum TG, TC and LDL-C, decreased atherogenic index, liver TG and liver TC content.
“Additionally, in a high-fat high fructose diet and STZ-induced diabetic insulin-resistant rat model, mangiferin was demonstrated to concurrently alleviate insulin resistance, improve β-cell function, reduce serum levels of triglyceride (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), as well decrease the atherogenic index, liver TG and liver TC content.”
From Mangiferin: An effective therapeutic agent against several disorders (Review) (2018) · cites this paper as [27]
In the same model, liver glycogen content was enhanced by mangiferin.
“Liver glycogen content was also enhanced (27).”
From Mangiferin: An effective therapeutic agent against several disorders (Review) (2018) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751 · see citing works
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · see citing works
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects
Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., Sugiyama, T., Miyagishi, M., Hara, K., Tsunoda, M., et al. (2003) · Nature · doi:10.1038/nature01705 · Cited by 3,176 · see citing works
Overweight and obesity in the United States: prevalence and trends, 1960–1994
Flegal, K., Carroll, M., Kuczmarski, R., & Johnson, C. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800541 · Cited by 3,045 · see citing works
Yoon, M. J., Lee, G. Y., Chung, J.-J., Ahn, Y. H., Hong, S. H., & Kim, J. B. (2006) · Diabetes · doi:10.2337/db05-1322 · Cited by 546 · see citing works
Guha, S., Ghosal, S., & Chattopadhyay, U. (2009) · Chemotherapy · doi:10.1159/000239478 · Cited by 275 · cited 2× · see citing works
“2000), antitumor (Guha et al. 1996), antiviral (Yoosook et al.”
BackgroundSellamuthu, P. S., Arulselvan, P., Muniappan, B. P., Fakurazi, S., & Kandasamy, M. (2013) · Journal of Medicinal Food · doi:10.1089/jmf.2012.2480 · Cited by 70 · see citing works
Flagged first, then by citations
Research works printed but not linked: 3
- CHANG SL, LIN JG, CHI TC, LIU IM AND CHENG JT. 1999. An insulin-dependent hypoglycaemia induced by electroacupuncture at the Zhongwan (CV12) acupoint in diabetic rats. Diabetologia 42: 250-255.
- LONARDO A, LOMBARDINI S, RICCHI M, SCAGLIONI F AND LORIA P. 2005. Review article: hepatic steatosis and insulin resistance. Aliment Pharmacol Ther 22 (Suppl 2): 64-70.
- SAXENA A AND VIKRAM NK. 2004. Role of selected Indian plants in management of type 2 diabetes: a review. J Altern Complement Med 10: 369-378.
Cited by
Sorted by citations
Mangiferin: A natural miracle bioactive compound against lifestyle related disorders
Imran, M., Arshad, M. S., Butt, M. S., Kwon, J.-H., Arshad, M. U., & Sultan, M. T. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0449-y · Cited by 366 · see citing works
Mangiferin: A xanthonoid with multipotent anti‐inflammatory potential
Saha, S., Sadhukhan, P., & Sil, P. C. (2016) · BioFactors · doi:10.1002/biof.1292 · Cited by 159 · see citing works
Pattnaik, M., Pandey, P., Martin, G. J. O., Mishra, H. N., & Ashokkumar, M. (2021) · Foods · doi:10.3390/foods10020279 · Cited by 146 · see citing works
Mangiferin: An effective therapeutic agent against several disorders (Review)
Du, S., Liu, H., Lei, T., Xie, X., Wang, H., He, X., Tong, R., & Wang, Y. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9529 · Cited by 139 · see citing works
“Liver glycogen content was also enhanced (27).”
Shaik Mohamed Sayed, U. F., Moshawih, S., Goh, H. P., Kifli, N., Gupta, G., Singh, S. K., Chellappan, D. K., Dua, K., Hermansyah, A., Ser, H. L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1182937 · Cited by 136 · see citing works
The management of diabetes mellitus by mangiferin: advances and prospects
Wang, M., Liang, Y., Chen, K., Wang, M., Long, X., Liu, H., Sun, Y., & He, B. (2022) · Nanoscale · doi:10.1039/d1nr06690k · Cited by 56 · see citing works
Wang, Y., Karmakar, T., Ghosh, N., Basak, S., & Gopal Sahoo, N. (2022) · Food Chemistry · doi:10.1016/j.foodchem.2021.131376 · Cited by 35 · see citing works
Pinneo, S., O'Mealy, C., Rosas Jr., M., Tsang, M., Liu, C., Kern, M., Hooshmand, S., & Hong, M. Y. (2022) · Journal of Medicinal Food · doi:10.1089/jmf.2021.0063 · Cited by 19 · see citing works
Suman, R. K., Borde, M. K., Mohanty, I. R., & Singh, H. K. (2023) · International Journal of Applied & Basic Medical Research · doi:10.4103/ijabmr.ijabmr_115_23 · Cited by 7 · see citing works
Alsaedi, A. Q., Nader, M. A., El-Kashef, D. H., & Abdelmageed, M. E. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1572758 · Cited by 5 · see citing works
- Authors
- SALEH, S., EL-MARAGHY, N., REDA, E., & BARAKAT, W.
- Affiliations
- Cairo University (EG)
- Zagazig University, Egypt; Future University, Egypt
- Zagazig University (EG)
- ORCID
- BARAKAT, WALEED
- Venue
- Anais da Academia Brasileira de Ciências
- Publisher
- FapUNIFESP (SciELO)
- Published
- 2014-12
- Volume
- 86
- Issue
- 4
- Pages
- 1935-1948
- ISSN
- 0001-3765 (ISSN-L)
- OpenAlex
- W2020694801
- Cited by
- 81
- References
- 7
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 5 · 2023: 8 · 2022: 6 · 2021: 10 · 2020: 5 · 2019: 12 · 2018: 9 · 2017: 8 · 2016: 9
- FWCI
- 12.13
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- Locations
- Anais da Academia Brasileira de Ciências (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
- Americanae (AECID Library) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Redalyc (Universidad Autónoma del Estado de México) (submittedVersion)
- Funders
- Zagazig University (8K2/M3)
- Topics
- Health Sciences › Medicine › Complementary and alternative medicine › Mangiferin and Mango Extracts
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- mangiferin, type 2 diabetes, insulin resistance, dyslipidemia, adiponectin, TNF-α, rosiglitazone, high-fat high-fructose diet, streptozotocin-induced diabetes, metabolic syndrome, liver glycogen, adipokines, natural compounds
- MeSH terms
- Rosiglitazone, Animals, Diabetes Mellitus, Experimental, Hypoglycemic Agents, Insulin Resistance, Male, Streptozocin, Tumor Necrosis Factor-alpha, Xanthones, Thiazolidinediones, Dyslipidemias, Rats, Adiponectin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
